潘莹,储悄悄,魏雪,黄红兵,刘韬
PAN Ying,CHU Qiaoqiao,WEI Xue,HUANG Hongbing,LIU Tao

• 1:华南肿瘤学国家重点实验室肿瘤医学协同创新中心中山大学肿瘤防治中心

摘要(Abstract)：

目的探讨我国药品不良反应监测中存在的问题和解决方法。方法对2011-01~2012-06中山大学肿瘤防治中心使用过利妥昔单抗、曲妥珠单抗、贝伐珠单抗、厄洛替尼的患者ADR发生情况进行抽查,并将抽查结果与该院以及广东地区ADR监测结果进行对比分析。结果 4种靶向药物在本院ADR上报率为0.0%~1.4%,抽查结果显示4种靶向药物在本院发生率为6.7%~30.0%;约18.9%患者可能发生与靶向药物相关ADR,而仅0.5%的ADR引起临床注意并上报。结论不良反应监测存在漏报现象,应从立法、处罚、报告制度、人才培养等方面进一步加强我国不良反应监测工作。
OBJECTIVE To investigate the problems and solutions of adverse drug reaction monitoring in China. METHODS A spot-check of ADR occurrence was conducted in hospitalized patients who were treated by rituximab,trastuzumab,bevacizumab and erlotinib in Sun Yat-sen University Cancer Center( SYSUCC) from January 2011 to June 2012. Then the incidence condition of adverse reaction of 4 targeted anticancer drugs was analyzed in these cases and the results were compared with the actually ADR monitoring results in SYSUCC and Guangdong region. RESULTS The reporting rate of ADR of 4 targeted anticancer agents was 0.0%- 1.4%,and the incidence of ADR of these 4 drugs was 6.7%-30.0% based on this survey,which means the side effects may occurred in about18.9% patients administrated with targeted therapy while only 0. 5% ADR got clinic attention and was reported. CONCLUSION Under-reporting of ADRs occurred in ADR reporting systems,and the ADR monitoring in China should be strengthened.

关键词(KeyWords)： 药品不良反应;靶向抗肿瘤药物;不良反应监测
adverse drug reaction;targeted anticancer drugs;ADR monitoring

Abstract:

Keywords:

基金项目(Foundation): 广东省药学会肝炎用药研究基金(2012G28);; 广东省自然科学基金项目(10451008901004256)

作者(Author): 潘莹,储悄悄,魏雪,黄红兵,刘韬
PAN Ying,CHU Qiaoqiao,WEI Xue,HUANG Hongbing,LIU Tao

参考文献(References)：

• [1]国家食品药品监督管理局密切关注发生在美国的罗氏公司瞒报事件[EB].http://www.sda.gov.cn/WS01/CL0027/73405.html
• [2]王建华.流行病学[M].第五版.北京:人民卫生出版社,2008:174-176.
• [3]董铎,吴桂芝,田春华,等.从药物警戒和药品不良反应监测制度探讨《药品管理法》尚待完善的有关内容[J].中国药物警戒,2009,6(2):65-68.
• [4]Rituximab side effects[EB].http://www.drugs.com/sfx/rituximab-side-effects.html
• [5]Trastuzumab side effects[EB].http://www.drugs.com/sfx/trastuzumab-side-effects.html
• [6]丁燕,吴洪斌.曲妥珠单抗的不良反应及处理[J].药物不良反应杂志,2003,5(6):388-389.
• [7]Canevari S,Raspagliesi F,Lorusso D.Bevacizumab treatment and quality of life in advanced ovarian cancer[J].Future Oncol,2013,9(7):951-954.
• [8]Syrigos KN,Karapanagiotou E,Boura P,et al.Bevacizumab-induced hypertension:pathogenesis and management[J].BioDrugs.2011,25(3):159-169.
• [9]BC Cancer Agency.Management Guidelines for BevacizumabRelated Side Effects in Patients with Colorectal Cancer[S].2006.
• [10]Product Information:TARCEVA(R)oral tablets,erlotinib oral tablets.Genentech USA,Inc.(per FDA),South San Francisco,CA,2012.
• [11]国家药品不良反应监测年度报告(2013年)[EB].http://www.sda.gov.cn/WS01/CL0078/99794.html
• [12]潘晓贇,马爱霞.中外药品不良反应监测体系的比较分析[J].药学进展,2005,29(4):183-186.
• [13]公培献,孔庆衍,周勇,等.我国药品不良反应监测体系建设有关制度研究[J].中国药物警戒,2009,6(2):74-79.